Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib and Particle Therapy in Head and Neck Adenoid Cystic Carcinoma
NCT02942693Phase 2Unknown
- Sponsor
- Shanghai Proton and Heavy Ion Center
- Start
- Nov 2016
- Primary completion
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Rivoceranib in adenoid cystic carcinoma (ACC), sponsored by Shanghai Proton and Heavy Ion Center. Status: unknown.
02
Drugs
Rivoceranib
03
Conditions
adenoid cystic carcinoma (ACC)
Beyond the preview
Go deeper on NCT02942693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02942693.